Business
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles)Data indicates INO-3107 was well
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles)Data indicates INO-3107 was well tolerated and has the potential to provide clinical benefit to adults with RRPPLYMOUTH MEETING, Pa., May 8, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts. The COSM is a major national meeting of otolaryngologists/head and neck surgeons and incorporates the scientific programs of eight participating professional societies including the ABEA.\nDr. Ted Mau, lead investigator and laryngologist at University of Texas Southwestern Medical Center, presented the new data during an oral presentation at the conference.\n\"The additional data on INO-3107 presented demonstrate immunogenicity and potential for efficacy,\" said Dr. Mau. \"INO-3107 reduced the need for surgical interventions for most trial participants – arguably the most important potential clinical benefit to patients living with this disease.\"\nDr. Jeffrey Skolnik, INOVIO's Senior Vice President of Clinical Development added: \"The data set we've analyzed from this trial indicate that INO-3107 could potentially provide a life-changing alternative to the current standard of care for RRP. We are focused on moving this candidate forward as quickly as possible to realize its potential for patients globally.\"\nIn February 2023, INOVIO announced positive preliminary results from the second (side port needle) cohort of its Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated RRP in adults. Positive results from the first (standard needle) cohort were shared in October 2022. At COSM, Dr. Mau presented combined safety and immunogenicity data from both cohorts.\nSafety highlights:\nINO-3107 was well-tolerated, with the most frequently reported treatment-emergent adverse events (TEAEs) r...